EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cefepime-Taniborbactam—a Novel Combination Therapy for Multidrug-Resistant Pathogens

Richard R Watkins, Tracy L Lemonovich iD, Alejandro J Vila, Robert A Bonomo iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf203 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Richard R Watkins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Northeast Ohio Medical University, Rootstown, Ohio, USA. Hauptthemen laut MEDLINE: Cefepime, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing spread of antimicrobial resistance has generated an urgent need for new antibiotics, especially against multidrug-resistant (MDR) gram-negative pathogens. Taniborbactam (previously VNRX-5133) is a novel bicyclic boronate β-lactamase inhibitor with potent, selective, and direct inhibitory activity against Ambler class A, B, C, and D enzymes, including serine and metallo-β-lactamases. Taniborbactam has a broader spectrum of inhibition than any other current β-lactamase inhibitor. The combination of cefepime with taniborbactam is in advanced clinical development. Investigators are studying the activity of cefepime-taniborbactam against gram-negative pathogens, including Enterobacterales species like carbapenem-resistant Klebsiella pneumoniae and MDR Pseudomonas aeruginosa with characterized carbapenem resistance mechanisms. In this review, we discuss the advances in medicinal chemistry that led to the development of cefepime-taniborbactam, the pharmacokinetics and pharmacodynamics, the antimicrobial spectrum of activity, potential uses in the clinic, and mechanisms of resistance. We propose future clinical scenarios to better explore the precise niche of this novel inhibitor combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefepimeAnti-Bacterial AgentsDrug Resistance, Multiple, Bacterialbeta-Lactamase InhibitorsGram-Negative BacteriaCephalosporinsHumansMicrobial Sensitivity TestsDrug Therapy, CombinationGram-Negative Bacterial InfectionsBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

antibioticsantimicrobial resistancecefepime-taniborbactamcephalosporinsgram-negative pathogens

Substanzen

CefepimeAnti-Bacterial Agentstaniborbactambeta-Lactamase InhibitorsCephalosporinsBorinic AcidsCarboxylic Acids

Autor:innen und Institutionen

  • Division of Infectious Diseases, Northeast Ohio Medical University, Rootstown, Ohio, USA.
  • Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, Ohio, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Instituto de Biología Molecular y Celular de Rosario, Santa Fe, Santa Fe, Argentina.
  • Área Biofísica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina.
  • Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

ORCID-Profile: Tracy L Lemonovich, Robert A Bonomo

Zitieren

APA

Watkins, R. R., Lemonovich, T. L., Vila, A. J., & Bonomo, R. A. (2025). Cefepime-Taniborbactam—a Novel Combination Therapy for Multidrug-Resistant Pathogens. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf203

Vancouver

Watkins RR, Lemonovich TL, Vila AJ, Bonomo RA. Cefepime-Taniborbactam—a Novel Combination Therapy for Multidrug-Resistant Pathogens. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf203

BibTeX
@article{Watkins2025,
  author = {Watkins, Richard R and Lemonovich, Tracy L and Vila, Alejandro J and Bonomo, Robert A},
  title = {Cefepime-Taniborbactam—a Novel Combination Therapy for Multidrug-Resistant Pathogens},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf203}
}
Kostenlos starten →